{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:39:31Z","timestamp":1791092371498,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.ahj.2010.06.049","type":"journal-article","created":{"date-parts":[[2010,10,10]],"date-time":"2010-10-10T04:14:15Z","timestamp":1286684055000},"page":"642-648.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial"],"prefix":"10.1016","volume":"160","clinical-trial-number":[{"clinical-trial-number":"nct01059136","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Farzin","family":"Beygui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vicaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Ecollan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Machecourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Van Belle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2010.06.049_bb0005","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/oxfordjournals.eurheartj.a060995","article-title":"Neurohormonal changes after acute myocardial infarction. Relationships with haemodynamic indices and effects of ACE inhibition","volume":"16","author":"Foy","year":"1995","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2010.06.049_bb0010","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0735-1097(94)90001-9","article-title":"Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril","volume":"24","author":"Rouleau","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2010.06.049_bb0015","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/0002-8703(93)90656-T","article-title":"Short- and long-term neurohormonal activation following acute myocardial infarction","volume":"126","author":"Sigurdsson","year":"1993","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2010.06.049_bb0020","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/01.CIR.97.22.2202","article-title":"Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group","volume":"97","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2010.06.049_bb0025","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/cs1030425","article-title":"Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy","volume":"103","author":"Farquharson","year":"2002","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.ahj.2010.06.049_bb0030","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0922-4106(95)90018-7","article-title":"Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta","volume":"290","author":"Ikeda","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ahj.2010.06.049_bb0035","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/01.CIR.0000015854.60710.10","article-title":"Mineralocorticoid receptor antagonism in experimental atherosclerosis","volume":"105","author":"Rajagopalan","year":"2002","journal-title":"Circulation"},{"issue":"12 Pt 1","key":"10.1016\/j.ahj.2010.06.049_bb0040","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S0895-7061(97)00301-4","article-title":"Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension","volume":"10","author":"Blacher","year":"1997","journal-title":"Am J Hypertens"},{"issue":"5 Suppl","key":"10.1016\/j.ahj.2010.06.049_bb0045","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1067\/mhj.2002.129969","article-title":"Aldosterone: cardiovascular assault","volume":"144","author":"Struthers","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2010.06.049_bb0050","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/01.CIR.0000097000.51723.6F","article-title":"Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II\/NG-nitro-l-arginine methyl ester-induced myocardial injury","volume":"108","author":"Oestreicher","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2010.06.049_bb0055","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","article-title":"Aldosterone: a mediator of myocardial necrosis and renal arteriopathy","volume":"141","author":"Rocha","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.ahj.2010.06.049_bb0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0008-6363(96)88542-7","article-title":"Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist","volume":"29","author":"Van Belle","year":"1995","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ahj.2010.06.049_bb0065","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/01.RES.0000080521.15238.E5","article-title":"Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure","volume":"93","author":"Qin","year":"2003","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2010.06.049_bb0070","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1161\/hc3001.091458","article-title":"Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries","volume":"104","author":"Ward","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2010.06.049_bb0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10741-005-2351-3","article-title":"Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure","volume":"10","author":"Zannad","year":"2005","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ahj.2010.06.049_bb0080","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1161\/CIRCULATIONAHA.106.634626","article-title":"High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction","volume":"114","author":"Beygui","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2010.06.049_bb0085","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ahj.2008.12.013","volume":"157","author":"Beygui","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2010.06.049_bb0090","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/eurheartj\/ehn383","article-title":"Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction","volume":"29","author":"Palmer","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2010.06.049_bb0095","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jama.284.7.835","article-title":"The TIMI risk score for unstable angina\/non\u2013ST elevation MI: a method for prognostication and therapeutic decision making","volume":"284","author":"Antman","year":"2000","journal-title":"Jama"},{"key":"10.1016\/j.ahj.2010.06.049_bb0100","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/j.jacc.2006.07.010","volume":"48","author":"Zipes","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2010.06.049_bb0105","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2010.06.049_bb0110","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2010.06.049_bb0115","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jacc.2005.04.038","article-title":"Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure","volume":"46","author":"Pitt","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2010.06.049_bb0120","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1161\/01.CIR.0000068340.96506.0F","volume":"107","author":"Hayashi","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2010.06.049_bb0125","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1161\/CIRCULATIONAHA.106.178233","volume":"114","author":"Zipes","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2010.06.049_bb0130","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(06)68147-6","article-title":"Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial","volume":"367","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2010.06.049_bb0135","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/eurheartj\/ehm031","article-title":"STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC\/ACC definition (the OPERA registry)","volume":"28","author":"Montalescot","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2010.06.049_bb0140","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/bjc.1976.220","article-title":"Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design","volume":"34","author":"Peto","year":"1976","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ahj.2010.06.049_bb0145","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1161\/CIRCULATIONAHA.107.187397","article-title":"Universal definition of myocardial infarction","volume":"116","author":"Thygesen","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2010.06.049_bb0150","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/jama.297.17.1892","article-title":"Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006","volume":"297","author":"Fox","year":"2007","journal-title":"Jama"},{"key":"10.1016\/j.ahj.2010.06.049_bb0155","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/hrt.2008.149922","article-title":"Delay to angiography and outcomes following presentation with high-risk, non\u2013ST-elevation acute coronary syndromes: results from the Global Registry of Acute Coronary Events","volume":"95","author":"Swanson","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2010.06.049_bb0160","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1016\/0006-2952(82)90658-X","article-title":"Cardiovascular and renal properties of potassium-sparing diuretics of the spirolactone group\u2014I: effects of SC-14266\/371 (potassium canrenoate) on renal transport Na+, K+-ATPase activity","volume":"31","author":"Osore","year":"1982","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ahj.2010.06.049_bb0165","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/eurheartj\/ehp555","article-title":"Cardioprotective effects of mineralocorticoid receptor antagonists at reperfusion","author":"Schmidt","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2010.06.049_bb0170","article-title":"Hyperaldosteronism in the acute phase of myocardial infarction. Effects of its treatment on the prevention of ventricular fibrillation","volume":"77","author":"Denis","year":"1984","journal-title":"Arch Mal Coeur Vaiss"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287031000565X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287031000565X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:42:07Z","timestamp":1757569327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000287031000565X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S000287031000565X"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2010.06.049","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2010.06.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}